Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
- 1 April 2000
- journal article
- Published by Elsevier BV in The Lancet
- Vol. 355 (9214), 1491-1498
- https://doi.org/10.1016/s0140-6736(00)02163-2
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Complete Androgen Blockade versus Chemical Castration in Advanced Prostatic Cancer: Analysis of an Italian Multicentre StudyUrologia Internationalis, 1998
- Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853European Urology, 1998
- Maximum Androgen Blockade Using LHRH Agonist Buserelin in Combination with Short-Term (Two Weeks) or Long-Term (Continuous) Cyproterone Acetate Is Not Superior to Standard Androgen Deprivation in the Treatment of Advanced Prostate CancerEuropean Urology, 1998
- Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate — an Australian multicentre trialBritish Journal of Urology, 1996
- A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostateEuropean Journal Of Cancer, 1995
- Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancerEuropean Journal Of Cancer, 1993
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)New England Journal of Medicine, 1989
- 10-Jahres-Ergebnisse einer randomisierten Prospektivstudie beim metastasierten ProstatakarzinomAktuelle Urologie, 1987
- Orchiectomy Combined with Cyproterone Acetate or Prednisone in the Treatment of Advanced Prostatic CarcinomaScandinavian Journal of Urology and Nephrology, 1982